Tipredane

Tipredane

SCHEMBL5488434

CCS[C@@]1(SC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 6/20 0.59
CYP3A4 P08684 6/20 0.59
LMNA P02545 3/20 0.59
ALDH1A1 P00352 1/20 0.59
NR3C1 P04150 6/20 0.56
HSD17B10 Q99714 4/20 0.56
PGR P06401 3/20 0.56
NFKB1 P19838 3/20 0.56
CYP2C9 P11712 2/20 0.56
PMP22 Q01453 2/20 0.56
CYP2J2 P51589 1/20 0.56
BLM P54132 1/20 0.56
CYP2C19 P33261 1/20 0.56
TSHR P16473 2/20 0.54
AR P10275 2/20 0.54
MEN1 O00255 1/20 0.54
CYP2D6 P10635 1/20 0.54
KMT2A Q03164 1/20 0.54
APEX1 P27695 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tipredane SCHEMBL10881217 1.00 HIF1A (0.59) HIF1ACYP3A4LMNAALDH1A1NR3C1
Tipredane SCHEMBL120921 1.00 HIF1A (0.59) HIF1ACYP3A4LMNAALDH1A1NR3C1
Tipredane SCHEMBL9569097 1.00 HIF1A (0.59) HIF1ACYP3A4LMNAALDH1A1NR3C1
Tipredane SCHEMBL10881220 1.00 HIF1A (0.59) HIF1ACYP3A4LMNAALDH1A1NR3C1
Tipredane SCHEMBL9569094 1.00 HIF1A (0.59) HIF1ACYP3A4LMNAALDH1A1NR3C1
Tipredane SCHEMBL9569099 1.00 HIF1A (0.59) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL11211400 0.95 HIF1A (0.61) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL11211398 0.95 HIF1A (0.61) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL11198668 0.94 HIF1A (0.58) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL10880778 0.94 HIF1A (0.58) HIF1ACYP3A4LMNAALDH1A1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070021360-A1 Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase EPIGENESIS PHARMACEUTICALS, LLC 2007-01-25 US claimed
EP-0073026-B1 17,17-BIS(SUBSTITUTED THIO)-3-KETOANDROSTENES AND PHARMACEUTICAL COMPOSITIONS E.R. Squibb & Sons, Inc. (US) 1986-03-19 EP claimed
EP-0524813-A1 Selective thioketalization process, process for preparing thioenol ethers from thioketals, and process for the preparation of thioketals E.R. SQUIBB & SONS, INC. (US) 1993-01-27 EP disclosed
EP-0316834-B1 STEROID CREAM FORMULATION E.R. Squibb & Sons, Inc. (US) 1992-06-24 EP disclosed
EP-0316815-B1 STEROID OINTMENT FORMULATION E.R. Squibb & Sons, Inc. (US) 1992-05-27 EP disclosed
US-4883792-A ANTIFUNGAL CREAM CONTAINING TIPREDANE E.R. SQUIBB & SONS, INC., A DE CORP. 1989-11-28 US disclosed
US-4868170-A ANTIINFLAMMATORY, OXIDATION RESISTANCE E. R. SQUIBB & SONS, INC. (US) 1989-09-19 US disclosed
US-4868169-A ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1989-09-19 US disclosed
EP-0316834-A1 Steroid cream formulation E.R. Squibb & Sons, Inc. (US) 1989-05-24 EP disclosed
EP-0316815-A1 Steroid ointment formulation E.R. Squibb & Sons, Inc. (US) 1989-05-24 EP disclosed
EP-0316815-A1 Steroid ointment formulation E.R. Squibb & Sons, Inc. (US) 1989-05-24 EP disclosed
EP-0105224-B1 ANDROSTENES AND PROCESS FOR THEIR PREPARATION E.R. Squibb & Sons, Inc. (US) 1987-01-21 EP disclosed
EP-0073026-B1 17,17-BIS(SUBSTITUTED THIO)-3-KETOANDROSTENES AND PHARMACEUTICAL COMPOSITIONS E.R. Squibb & Sons, Inc. (US) 1986-03-19 EP disclosed
US-4446071-A Intermediates useful in the preparation of 17,17-bis(substituted thio) androstenes E. R. SQUIBB & SONS, INC. (US) 1984-05-01 US disclosed
EP-0105224-A2 Androstenes and process for their preparation E.R. Squibb & Sons, Inc. (US) 1984-04-11 EP disclosed
US-4435326-A Intermediates useful in the preparation of 17,17-bis(substituted thio)androstenes E. R. SQUIBB & SONS, INC. (US) 1984-03-06 US disclosed
EP-0073026-A1 17,17-Bis(substituted thio)-3-ketoandrostenes and pharmaceutical compositions E.R. Squibb & Sons, Inc. (US) 1983-03-02 EP disclosed
US-4361559-A TOPICAL ADMINISTRATION FOR SKIN DISORDERS OF ASTHMA E. R. SQUIBB & SONS, INC. (US) 1982-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021360-A1 Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase RECQL, GSS, DDX17 HIF1A 1076/4885CYP3A4 2529/4885LMNA 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.